Clinical Challenges
Article

Hyperviscosity Syndrome in Patients With Multiple Myeloma

Ellen C. Mullen

Noel Mendez

adverse event management
ONF 2008, 35(3), 350-352. DOI: 10.1188/08.ONF.350-352

Jump to a section

    References

    Cook, L., & MacDonald, D. H. (2007). Management of paraproteinaemia. Postgraduate Medical Journal, 83(978), 217-223.
    Drew, M. J. (2002). Plasmapheresis in the dysproteinemias. Therapeutic Apheresis, 6(1), 45-52.
    Ghobrial, I. M., Gertz, M. A., & Fonseca, R. (2003). Waldenstrom macroglobulinemia. Lancet Oncology, 4(11), 679-685.
    Kundu, S., Dey, A., & Sengupta, A. (2003). Hyperviscosity syndrome with pulmonary involvement. Journal of the Indian Medical Association, 101(9), 552-553.
    Mehta, J., & Singhal, S. (2003). Hyperviscosity in plasma cell dyscrasias. Seminars in Thrombosis and Hemostasis, 29(5), 467-471.
    National Comprehensive Cancer Network. (2007). Clinical practice guidelines in oncology: Multiple myeloma (Version 3). Retrieved September 6, 2007, from http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf
    Park, M. S., Kim, B. C., Kim, I. K., Lee, S. H., Choi, S. M., Kim, M. K., et al., (2005). Cerebral infarction in IgG multiple myeloma with hyperviscosity. Journal of Korean Medical Science, 20(4), 699-701.
    Rampling, M. W. (2003). Hyperviscosity as a complication in a variety of disorders. Seminars in Thrombosis and Hemostasis, 29(5), 459-465.
    Syms, M. J., Arcila, M. E., & Holtel, M. R. (2001). Waldenstrom's macroglobulinemia and sensorineural hearing loss. American Journal of Otolaryngology, 22(5), 349-353.
    Wong, P. N., Mak, S. K., Lo, K. Y., Tong, G. M., & Wong, A. K. (2000). Acute tubular necrosis in a patient with Waldenstrom's macroglobulinemia and hyperviscosity syndrome. Nephrology, Dialysis, Transplantation, 15(10), 1684-1687.
    Zarkovic, M., & Kwaan, H. C. (2003). Correction of hyperviscosity by apheresis. Seminars in Thrombosis and Hemostasis, 29(5), 535-542.
    Chiang, C. C., Begley, S., & Henderson, S. O. (2000). Central retinal vein occlusions due to hyperviscosity syndrome. Journal of Emergency Medicine, 18(1), 23-26.
    Colson, K., Doss, D., Swift, R., Tariman, J., & Thomas, T. E. (2004). Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: Nursing implications. Clinical Journal of Oncology Nursing, 8(5), 473-480.
    Cook, L., & MacDonald, D. H. (2007). Management of paraproteinaemia. Postgraduate Medical Journal, 83(978), 217-223.
    Hemingway, T. J., & Savitsky, E. J. (2007). Hyperviscosity syndrome. Retrieved September 6, 2007, from http://www.emedicine.com/emerg/topic756.htm
    Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007). Cancer statistics, 2007. CA: A Cancer Journal for Clinicians, 57(1), 43-66.
    Kundu, S., Dey, A., & Sengupta, A. (2003). Hyperviscosity syndrome with pulmonary involvement. Journal of Indian Medical Association, 101(9), 552-553.
    National Comprehensive Cancer Network. (2007). Clinical practice guidelines in oncology: Multiple myeloma v.3.0. Retrieved September 6, 2007, from http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf
    Park, M. S., Kim, B. C., Kim, I. K., Lee, S. H., Choi, S. M., Kim, M. K., et al. (2005). Cerebral infarction in IgG multiple myeloma with hyperviscosity. Journal of Korean Medical Science, 20(4), 699-701.
    Rampling, M. W. (2003). Hyperviscosity as a complication in a variety of disorders. Seminars in Thrombosis and Hemostasis, 29(5), 459-465.
    Wong, P. N., Mak, S. K., Lo, K. Y., Tong, G. M., & Wong, A. K. (2000). Acute tubular necrosis in a patient with Waldenstrom's macroglobulinemia and hyperviscosity syndrome. Nephrology, Dialysis, Transplantation, 15(10), 1684-1687.